Belite Bio (BLTE) reported a Q3 net loss Tuesday of $0.28 per diluted share, narrowing from a loss of $0.40 a year earlier.
Analysts surveyed by Capital IQ expected a loss of $0.29.
The company did not report any revenue for the quarter ended Sept. 30, as expected.
As of Sept. 30, the company had $109 million in cash, money market fund, time deposits and US treasury bills, it said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。